Patents by Inventor Nathan BEALS

Nathan BEALS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macropinocytosis selective monobody-drug conjugates
    Patent number: 12642859
    Abstract: The present disclosure is directed to pharmaceutical and diagnostic compositions comprising macropinocytosis selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain coupled to a pharmaceutically active moiety or a diagnostic moiety. The disclosure is also directed to methods of treatment and diagnosis that involve administering the pharmaceutical compositions described herein to a subject in need.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: June 2, 2026
    Assignee: NEW YORK UNIVERSITY
    Inventors: Craig Ramirez, Andrew Hauser, Nathan Beals, Dafna Bar-Sagi, Akiko Koide, Shohei Koide
  • Modulating Human Tyrosine Hydroxylase Expression Through Control of Specific G-Quadruplex Formation
    Publication number: 20240294919
    Abstract: Novel DNA molecule-based compositions and methods for delivery to target cells provide modulation of target G-quadruplex formation in the tyrosine hydroxylase (TH) promoter and allow for enhancement or repressing of specific G-quadruplexes that in turn regulate tyrosine hydroxylase transcription and catecholamine production, specifically dopamine. Use of the DNA-molecule-based compositions in treatment of neurological diseases and disorders is facilitated through a nanoparticle-based delivery system.
    Type: Application
    Filed: May 25, 2022
    Publication date: September 5, 2024
    Inventors: Soumitra BASU, Nathan BEALS, Mohamed M. FARHATH, Prakash KHAREL
  • MACROPINOCYTOSIS SELECTIVE MONOBODY-DRUG CONJUGATES
    Publication number: 20240016944
    Abstract: The present disclosure is directed to pharmaceutical and diagnostic compositions comprising macropinocytosis selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain coupled to a pharmaceutically active moiety or a diagnostic moiety. The disclosure is also directed to methods of treatment and diagnosis that involve administering the pharmaceutical compositions described herein to a subject in need.
    Type: Application
    Filed: November 10, 2021
    Publication date: January 18, 2024
    Inventors: Craig RAMIREZ, Andrew HAUSER, Nathan BEALS, Dafna BAR-SAGI, Akiko KOIDE, Shohei KOIDE